Methocarbamol-Associated Cardiovascular Risks

Introduction to Methocarbamol Risks

• Methocarbamol can cause hypotension and bradycardia as documented adverse cardiovascular effects, and should be held on the day of surgical procedures due to these risks, as recommended by the Society for Perioperative Assessment and Quality Improvement (SPAQI) 1

Perioperative Considerations and Special Populations

• The Society for Perioperative Assessment and Quality Improvement (SPAQI) recommends holding methocarbamol on the day of surgical procedures due to its cardiovascular effects and potential interactions with anesthetic agents 1
• The American Heart Association notes that methocarbamol can be used for musculoskeletal pain in patients with end-stage cardiovascular disease, but clinicians must be aware that anxiolytics and sedating medications can significantly increase the risk of falls when combined with antihypertensive agents and diuretics 2

Drug Interactions and Patient Monitoring

• The hypotensive effect of methocarbamol can be amplified by concurrent use with antihypertensive medications, diuretics, and other sedating agents, according to the American Heart Association 2
• Methocarbamol elimination is significantly impaired in patients with liver and kidney disease, which can lead to drug accumulation and increased risk of adverse effects including hypotension, as reported by the Mayo Clinic Proceedings 1

Patient Management and Precautions

• The American Heart Association recommends exercising caution in elderly patients who are more susceptible to orthostatic hypotension and falls, especially when taking concurrent antihypertensives 2
• Methocarbamol should not be used in patients with myasthenia gravis as it interferes with pyridostigmine bromide effects, and abrupt discontinuation should be avoided in long-term users, as advised by the Mayo Clinic Proceedings 1